Advertisement

Topics

Combining immune-based therapies with TKIs in melanomas

10:10 EDT 4 Jul 2017 | ecancermedicalscience

Prof Robert speaks with ecancer at WIN 2017 about tackling class-associated toxicity and drug resistance with combination therapies based on tyrosine kinase inhibition. Intralesional oncolytic therapies for melanoma were also discussed by Dr Sanjiv...

Original Article: Combining immune-based therapies with TKIs in melanomas

NEXT ARTICLE

More From BioPortfolio on "Combining immune-based therapies with TKIs in melanomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....